Trial Profile

Bupivacaine Effectiveness and Safety in SABER Trial (BESST)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bupivacaine (Primary)
Indications Postoperative pain
Focus Pharmacokinetics; Registrational; Therapeutic Use
Acronyms BESST
Sponsors DURECT Corporation

Most Recent Events

16 May 2014 According to the DURECT corporation media release, cardiac safety data from this trial were presented at the International Anesthetic Research Society (IARS) Annual Meeting.
05 Jan 2012 Primary endpoint 'Additional-treatment-required---rescue-medication' has not been met.
05 Jan 2012 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com